Is NCT07308886 recruiting in Bethesda, MD?

Yes, NCT07308886 is currently recruiting participants at its Bethesda, MD location. This kaposi sarcoma clinical trial is actively enrolling qualified participants.

How do I join the kaposi sarcoma clinical trial in Bethesda?

To join this clinical trial in Bethesda, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Bethesda clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Kaposi Sarcoma Clinical Trial in Bethesda, MD

About This Kaposi Sarcoma Study in Bethesda

Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus. People infected with human immunodeficiency virus (HIV) account for 80% of KS cases in the United States. Having HIV can weaken the immune system and this can lead to KS. Weaker immune systems may be measured by low T cells (a type of immune cell). CYT107 is a human protein, made in a laboratory, that may help boost immunity, specifically by increasing T cells, in people with HIV-associated KS. Objective: To see if CYT107 can shrink KS tumors. Eligibility: People aged 18 years and older with HIV-associated KS. Design: Participants will be screened. They will have a physical exam with blood tests. Their skin lesions will be measured. They will have an x-ray of their lungs. Their ability to perform everyday tasks will be reviewed. A sample of lesion tissue (biopsy) may be collected from the skin. CYT107 is injected into the muscle of the arm, buttocks, or lower thigh once a week for up to 4 weeks. Participants will receive the shots at the clinic. Blood and other tests will be repeated at each visit. KS lesions will be measured and photographed on the 1st and 4th visits. Participants who improved after the first 4 weeks may have another 4-week treatment within a year. Follow-up visits will continue for 3 years.

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

Histologically confirmed KS by NCI Laboratory of Pathology (LP), with or without any prior systemic KS treatment

Participants with HIV infection

Age \>= 18 years

All participants should have at least five (5) measurable cutaneous KS lesions with no previous local radiation, surgical or intralesional cytotoxic therapy that would prevent response assessment for that lesion.

Participants with stage T1 KS with visceral involvement must:

have any/all associated tumor associated symptoms \<= Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) v.6.0 criteria and/or,

require no immediate intervention (e.g., mild oozing of oral KS is allowed).

Participants did not receive prior systemic therapy for KS or received prior systemic therapy and currently are either plateau in response, relapsed disease, progressive disease (PD), or inadequate response to treatment. Note: Previous local therapy or radiation is not considered systemic therapy.

Participants must:

have been on effective ART therapy for at least 2 months prior to the study drug initiation and

have HIV VL \<= 100 copies/mL and

have persistent KS, affecting quality of life due to either T1 or T0 disease with inadequate disease regression on ART alone.

ECOG PS \<=3

Adequate organ and marrow function as defined below:

absolute neutrophil count (ANC) \>= 500/mcL

platelets \>= 50,000/mcL

hemoglobin (hgb) \>= 8g/dL

total bilirubin \<= 1.5 institutional upper limit of normal (iULN) or \<3 x iULN for Gilbert s syndrome or HIV protease inhibitors

AST \<= 2.5 x iULN

ALT \<= 2.5 x iULN

CD4 T-cell count \<= 350/mcL

Participants must be willing to co-enroll to protocol 17C0174 "Molecular Characterization of Viral-associated Tumors, Tumors occurring in the Setting of HIV or other Immune Disorders and Castleman Disease"

Participants with chronic hepatitis B virus (HBV) infection are eligible if they are on suppressive antiviral therapy.

Participants with a hepatitis C virus (HCV) infection must have an undetectable HCV VL due to prior treatment or natural resolution.

Women of child-bearing potential (WOCBP) and men able to father a child must agree to use an effective method of contraception (hormonal, barrier, surgical sterilization, abstinence) at the study entry, for the duration of study therapy, and for up to 4 months after discontinuation of study drug.

Nursing participants must be willing to discontinue nursing from study treatment initiation through 4 months after the last dose of the study drug.

Participants must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria

-Participants who have not recovered from immune-related AEs due to prior therapy (i.e., have residual toxicities \> Grade 1 per CTCAE v.6.0). Note: Participants with hypothyroidism managed by supplemental levothyroxine are eligible.

History of severe allergic, anaphylactic, or other hypersensitivity reactions to Chinese Hamster Ovary (CHO) cell products, chimeric or humanized antibodies or fusion proteins.

Participants must not have received chemotherapy, radiotherapy, or other KS directed therapy other than ART for HIV within 2 weeks before the initiation of study drug.

Participants must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) or systemic immunostimulatory agents (including, but not limited to, interferon \[IFN\]-alpha or IL-2, pomalidomide, or immune checkpoint inhibitors) within 2 weeks before initiation of study treatment. Note: Participants who have received acute, low dose of systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. The use of inhaled corticosteroids, and mineralocorticoids (e.g., fludrocortisone) for participants with orthostatic hypotension or adrenocortical insufficiency is allowed.

History or risk of autoimmune disease, except for:

the presence of laboratory evidence of autoimmune disease (e.g., history of positive antinuclear antibody \[ANA\] titer or lupus anticoagulant) without associated symptoms,

clinical evidence of vitiligo or other forms of depigmenting illness; and/or,

mild autoimmunity not impacting the function of major organs (e.g., limited psoriasis).

History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (e.g., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest x-ray. Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

History of allogeneic stem cell transplant and all other organ transplant.

Another prior or concurrent malignancy requiring active therapy

Active tuberculosis

Positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test at screening.

Participants must not have received prohibited therapies within 4 weeks before initiation of study treatment

Severe uncontrolled intercurrent illness that would limit compliance with study requirements, as evaluated by history, physical exam, and chemistry panel.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bethesda?

Yes, this clinical trial (NCT07308886) has an active research site in Bethesda, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Kaposi Sarcoma Treatment Options in Bethesda, MD

If you're searching for kaposi sarcoma treatment options in Bethesda, MD, this clinical trial (NCT07308886) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bethesda research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced kaposi sarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all kaposi sarcoma clinical trials near you to find additional studies recruiting in your area.

Kaposi Sarcoma Clinical Trial in Bethesda, MD

Expert Care in Bethesda

IRB Approved

No-Cost Care

Apply for This Bethesda Location

Why Participate?

Simple Process